Clinical Trials
54 trialsNational Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
FIRSTLUNG
Delfi Diagnostics Inc.
ARROW
Hoffmann-La Roche
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Immuneering Corporation
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
Creative Biosciences (Guangzhou) Co., Ltd.
ROOT
Taproot Health
KEYNOTE-782
Merck Sharp & Dohme LLC
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Advaxis, Inc.
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Icahn School of Medicine at Mount Sinai
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
Morphotek
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Mural Oncology, Inc
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
Checkpoint Therapeutics, Inc.
EUCROSS
University of Cologne
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Novartis
ALTA-1L
Takeda
APICAL
Chonnam National University Hospital
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
Mayo Clinic
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
Endocyte
TARGET
Endocyte
NIRPA
Gary Onik MD
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
Acrotech Biopharma Inc.
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Dana-Farber Cancer Institute
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer
University of Rochester
ALK
Instituto Nacional de Cancerologia de Mexico
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
ValiSeek Limited
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
Sunesis Pharmaceuticals
ABOUND 70+
Celgene
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Boehringer Ingelheim
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
Mayo Clinic
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
National Institutes of Health Clinical Center (CC)
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
Sanofi
Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Celldex Therapeutics
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
Novartis
TPEIAL
Hunan Province Tumor Hospital
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Memorial Sloan Kettering Cancer Center
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Endocyte
MDX1106-01
Bristol-Myers Squibb
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Sun Yat-sen University
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Memorial Sloan Kettering Cancer Center
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
Pfizer
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
National Cancer Center, Korea